Form 4: Candel Therapeutics Chief Technology Officer Sells Shares to Cover Tax Obligations

Candel Therapeutics' Chief Technology Officer, Seshu Tyagarajan, sold 20,392 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Seshu Tyagarajan, the Chief Technology Officer of Candel Therapeutics, sold 20,392 shares of common stock on November 29, 2024.
• The sale was executed at a price of $4.5556 per share.
• This transaction was not a discretionary sale but was required to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Mr. Tyagarajan directly owns 125,657 shares of Candel Therapeutics common stock.

Sentiment

Score: 5

Explanation: This is a neutral event, as the sale was not discretionary but rather to cover tax obligations. It does not indicate a change in the executive's view of the company's prospects.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across publicly traded companies.
• The number of shares sold and the price are specific to Candel Therapeutics and its stock compensation plan.
• Similar transactions are regularly reported by executives at other biotech companies.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but this transaction is not expected to have a significant impact on stakeholders.

Key Dates

Keywords

Candel Therapeutics, insider trading, stock sale, Form 4, Seshu Tyagarajan, tax obligations, restricted stock units